CODAGENIX
Chemicals & Related Products · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3 Bioscience Park Dr, Farmingdale, New Y...Phone Number
(631) 227-3932Website
www.codagenix.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CODAGENIX
Codagenix is a biotechnology company that combines codon deoptimization with live-attenuated viruses to create a transformative vaccine and therapeutic platform aimed at addressing global health challenges. Utilizing a proprietary synthetic biology approach, the company designs precise edits into viral genomes to develop solutions for infectious diseases that offer the immunity benefits of live-attenuated viruses while ensuring safety, speed, and scalability. Their innovative technology positions them to tackle significant threats in infectious disease. Codagenix is actively seeking to build a team of pioneers dedicated to advancing global health.Explore more
CODAGENIX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CODAGENIX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
CODAGENIX, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if CODAGENIX had a recent Job posting/layoffs
Check if CODAGENIX has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when CODAGENIX launches new products
Congratulate Masked Content for being promoted to Masked Content at CODAGENIX
Earning: See what the market has to say on CODAGENIX recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if CODAGENIX is spiking on competitors!
Funding: Get notified immidiatlly once CODAGENIX has new funding data
Recommended Actions
Find VP level buyers at CODAGENIX
Find more new buyers
Compare Similar Companies to CODAGENIX
Compare insights from companies similar to CODAGENIX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CODAGENIX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CODAGENIX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CODAGENIX.
CODAGENIX financials insights
Gather financial insights about CODAGENIX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Multiple Rounds
$2M
2015
Series A
$2M
2023
Series B
$45M
CODAGENIX Tech Stack
A closer look at the technologies used by CODAGENIX
Most Recent Scoops
Left Company
Executive Move
New Hire
Executive Move
Funding
New Hire
Executive Move
CODAGENIX News & Media
Codagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue Vaccine
Award valued at $5.88 million will support activities to advance CodaVax-DENV into the clinic FARMINGDALE, N.Y., Oct. 24, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology...Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv™ at IDWeek 2023
Results demonstrate CoviLiv, a novel intranasal live-attenuated COVID-19 vaccine candidate, induces robust humoral and cellular immunity in healthy adults CoviLiv is being investigated in ongoing Phase 3 efficacy study as part of the World Health Organization's Solidarity Trial Vaccines...Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV Vaccine, CodaVax™- RSV, in a Pediatric Population
Study is assessing safety and immunogenicity of CodaVax™- RSV in healthy children aged six months to five years FARMINGDALE, N.Y., May 10, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and...Codagenix Appoints Kimber Poffenberger, Ph.D., as Chief Strategy Officer
Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics,... Read More The post Codagenix Appoints Kimber Poffenberger, Ph.D., as Chief Strategy Officer appeared first on citybiz.
Read more news
Top Chemicals & Related Products Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CODAGENIX
Sign Up For FreeTo access detailed company insights
Codagenix is a biotechnology company that combines codon deoptimization with live-attenuated viruses to create a transformative vaccine and therapeutic platform aimed at addressing global health challenges. Utilizing a proprietary synthetic biology approach, the company designs precise edits into viral genomes to develop solutions for infectious di... Read More
